Cargando…

A Combination of Glucagon-Like Peptide-1 Receptor Agonist and Dietary Intervention Could Be a Promising Approach for Obesity Treatment

Detalles Bibliográficos
Autor principal:	Lee, Chooi Yeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489573/ https://www.ncbi.nlm.nih.gov/pubmed/34616367 http://dx.doi.org/10.3389/fendo.2021.748477

Ejemplares similares

Effect of dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist on weight loss in subjects with obesity
por: Zaffina, Isabella, et al.
Publicado: (2023)

A Glucagon-Like Peptide-1 Receptor Agonist Lowers Weight by Modulating the Structure of Gut Microbiota
por: Zhao, Li, et al.
Publicado: (2018)

It Is Time to Consider Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth
por: Oberle, Megan M., et al.
Publicado: (2019)

Utilization of glucagon-like peptide-1 receptor agonists in children and adolescents in China: a real-world study
por: Yan, Yilong, et al.
Publicado: (2023)

Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis
por: Wong, Chloe, et al.
Publicado: (2021)

Comparison of the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Metabolic Associated Fatty Liver Disease: Updated Systematic Review and Meta-Analysis
por: Dai, Yuzhao, et al.
Publicado: (2021)

Can glucagon-like peptide-1 receptor agonists cause acute kidney injury? An analytical study based on post-marketing approval pharmacovigilance data
por: Dong, Shichao, et al.
Publicado: (2022)

Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review
por: Xie, Zeyu, et al.
Publicado: (2023)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
por: Seghieri, Marta, et al.
Publicado: (2018)

GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
por: Wang, Jing-Yue, et al.
Publicado: (2023)

Glucagon-like peptide-1 receptor overexpression in cancer and its impact on clinical applications
por: Körner, Meike, et al.
Publicado: (2012)

The Interplay of Glucagon-Like Peptide-1 Receptor Trafficking and Signalling in Pancreatic Beta Cells
por: Marzook, Amaara, et al.
Publicado: (2021)

Dissecting the Physiology and Pathophysiology of Glucagon-Like Peptide-1
por: Paternoster, Silvano, et al.
Publicado: (2018)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017)

Real-world national trends and socio-economic factors preference of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in China
por: Li, Cao, et al.
Publicado: (2022)

Fixed-ratio combinations of basal insulin and glucagon-like peptide-1 receptor agonists as a promising strategy for treating diabetes
por: Nomoto, Hiroshi
Publicado: (2023)

Role of Glucagon-Like Peptide-1 Receptor Agonists in the Management of Non-Alcoholic Steatohepatitis: A Clinical Review Article
por: Ghazanfar, Haider, et al.
Publicado: (2021)

The Gut–Brain-Axis as a Target to Treat Stress-Induced Obesity
por: Lee, Chooi Yeng, et al.
Publicado: (2014)

Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists
por: Kang, Yu Mi, et al.
Publicado: (2016)

How glucagon-like peptide 1 receptor agonists work
por: Andreasen, Christine Rode, et al.
Publicado: (2021)

GRK Inhibition Potentiates Glucagon-Like Peptide-1 Action
por: Lee, Seunghun P., et al.
Publicado: (2021)

Structural and Molecular Conservation of Glucagon-Like Peptide-1 and Its Receptor Confers Selective Ligand-Receptor Interaction
por: Moon, Mi Jin, et al.
Publicado: (2012)

Role of Glucagon-Like Peptide-1 Receptor Agonists on the Weight Loss of Individuals With Type 2 Diabetes: A Systematic Review
por: Irfan, Huma, et al.
Publicado: (2023)

Is Glucagon Receptor Activation the Thermogenic Solution for Treating Obesity?
por: Conceição-Furber, Ellen, et al.
Publicado: (2022)

Synthesis and biological evaluation of glucagon-like peptide-1 receptor agonists
por: Zhang, Yu-Juan, et al.
Publicado: (2013)

Glucagon‐like peptide‐1 receptor agonists and their effects on weight reduction
por: Shin, Shyi‐Jang
Publicado: (2012)

Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
por: Hinnen, Deborah
Publicado: (2017)

The potential of glucagon-like peptide-1 receptor agonists in heart failure
por: Kreiner, Frederik Flindt, et al.
Publicado: (2022)

Glucagon-like peptide-1 receptor agonists in patients treated with antipsychotics
por: Delgado, A., et al.
Publicado: (2021)

Glucagon-Like Peptide-1 Receptor Agonists for Chronic Weight Management
por: Wojtara, Magda, et al.
Publicado: (2023)

Successful Resolution of Glucose Toxicity With the Use of Fixed-Ratio Combination Injection of Basal Insulin and Short-Acting Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist
por: Miura, Hiroshi, et al.
Publicado: (2022)

Improved systemic half-life of glucagon-like peptide-1-loaded carbonate apatite nanoparticles in rats
por: Ibnat, Nabilah, et al.
Publicado: (2022)

SUN-236 Testosterone and Glucagon-Like Peptide-1 Agonists for Type 2 Diabetes Mellitus: A Prospective Cohort Study
por: Graybill, Sky
Publicado: (2019)

Reversal of Obesity and Insulin Resistance by a Non-Peptidic Glucagon-Like Peptide-1 Receptor Agonist in Diet-Induced Obese Mice
por: He, Min, et al.
Publicado: (2010)

Ghrelin Is a Regulator of Glucagon-Like Peptide 1 Secretion and Transcription in Mice
por: Lindqvist, Andreas, et al.
Publicado: (2017)

The Impact of Glucagon-Like Peptide-1 on Bone Metabolism and Its Possible Mechanisms
por: Zhao, Chenhe, et al.
Publicado: (2017)

Association of glucagon‐like peptide‐1 receptor‐targeted imaging probe with in vivo glucagon‐like peptide‐1 receptor agonist glucose‐lowering effects
por: Murakami, Takaaki, et al.
Publicado: (2020)

Oral Semaglutide, the First Ingestible Glucagon-Like Peptide-1 Receptor Agonist: Could It Be a Magic Bullet for Type 2 Diabetes?
por: Kim, Hwi Seung, et al.
Publicado: (2021)

Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
por: Saraiva, Francisco Kerr, et al.
Publicado: (2014)

A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide
por: Gurung, Tara, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_9ijovnanp8k01sm4bjfni83iih